A study of TRT therapy for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy called TRTs for people with advanced cancers like stomach, esophagus, cervical, breast, or lung cancer that no longer respond to standard treatments. The therapy uses your own tumor tissue or fluid to create a personalized treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced cancer that has not been helped by standard treatments.
- You have a tumor sample or fluid that can be used to make the therapy.
- You are healthy enough for daily activities (ECOG score 0-1).
- Your blood, heart, lung, and kidney functions are within safe ranges.
- You have not had certain severe side effects from prior immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a type of immune-cell treatment made from T cells for people with advanced stomach or stomach-where-esophagus-meets-cancer that has come back or progressed after first chemotherapy. It aims to see whether these cells can control the cancer and improve outcomes after standard treatment has not worked.
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
This trial tests a personalized cell therapy (TCR-T cells) designed to target HPV-16 positive cancer cells. It may be an option for people with advanced cervical, head and neck, or anal cancer who have tried standard treatments without success.
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
This trial tests a new type of immune cell therapy called TCR-T that targets a specific genetic change (KRAS mutation) found in some pancreatic, colorectal, and lung cancers. If you have the right genetic markers and previous treatments haven't worked, this study may offer a new option.
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.